2026 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 3017628
Ellebaek, Eva, Weichenthal, Michael, Gavrilova, Iva, Asher, Nethanel, Terheyden, Patrick, Utikal, Jochen, Suljeviić, Amina Jalovčić, Pföhler, Claudia, Stojkovski, Igor, Herbst, Rudolf Alexander, Ugurel, Selma, Ruhlmann, Christina, Berrocal, Alfonso, Majem, Margarita, Dujovic, Branko, Šabarić, Viktor, Duvancic, Tomislav, Soria, Ainara, Donia, Marco, Schmidt, Henrik, Friis, Rasmus B., Gerasimov, Alexander, Shalamanova-Deleva, Gergana, Kontilev, Ahmed, Lev-Ari, Shaked, Shapira, Ronnie, Piccin, Luisa, Minisini, Alessandro, Özdemir, Berna C., Teterycz, Pawel, Mariuk-Jarema, Anna, Ziogas, Dimitrios, Anastasopoulou, Amalia, Stefanou, Dimitra, Gutiérrez, Lourdes, Gebhardt, Christoffer, Dummer, Reinhard, Hauschild, Axel, Mohr, Peter, von Wasielewski, Imke, Meier, Friedegund, Haanen, John, Svane, Inge Marie, Ascierto, Paolo A., Mangana, Joanna, Rutkowski, Piotr, Gogas, Helen, Bastholt, Lars, and Schadendorf, Dirk. “Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study”. EJC Skin Cancer 4 (2026): 100773.
PUB |
DOI |
WoS